PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29127458-0	2018	Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases.	BI 655064	72-81	CD40 molecule	Homo sapiens	104-108	
29127458-10	2018	CONCLUSIONS: Single doses up to 120 mg BI 655064 IV and SC were well tolerated and showed a high potential to block the CD40-CD40L pathway, supporting further clinical development of BI 655064 in patients with autoimmune disease.	BI 655064	39-48	CD40 molecule	Homo sapiens	120-124	
29127458-10	2018	CONCLUSIONS: Single doses up to 120 mg BI 655064 IV and SC were well tolerated and showed a high potential to block the CD40-CD40L pathway, supporting further clinical development of BI 655064 in patients with autoimmune disease.	BI 655064	183-192	CD40 molecule	Homo sapiens	120-124	
34624444-4	2021	Herein, we describe the generation and characterization of BI 655064, a novel, purely antagonistic anti-CD40 antibody that potently neutralizes CD40-CD40L-dependent B-cell stimulation without evidence of impacting platelet functions.	BI 655064	59-68	CD40 molecule	Homo sapiens	104-108	
34624444-4	2021	Herein, we describe the generation and characterization of BI 655064, a novel, purely antagonistic anti-CD40 antibody that potently neutralizes CD40-CD40L-dependent B-cell stimulation without evidence of impacting platelet functions.	BI 655064	59-68	CD40 molecule	Homo sapiens	144-148	
33047859-7	2021	Ninety percent inhibition of CD40 RO was achieved with doses >=120 mg, and a direct relationship between BI 655064 plasma concentration and inhibition of CD40 RO was observed.	BI 655064	105-114	CD40 molecule	Homo sapiens	29-33	
33047859-7	2021	Ninety percent inhibition of CD40 RO was achieved with doses >=120 mg, and a direct relationship between BI 655064 plasma concentration and inhibition of CD40 RO was observed.	BI 655064	105-114	CD40 molecule	Homo sapiens	154-158	
30902820-0	2019	Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study.	BI 655064	11-20	CD40 molecule	Homo sapiens	43-47	
30902820-1	2019	OBJECTIVE: To evaluate the safety, efficacy and therapeutic mechanism of BI 655064, an antagonistic anti-CD40 monoclonal antibody, in patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX-IR).	BI 655064	73-82	CD40 molecule	Homo sapiens	105-109	
30902820-6	2019	BI 655064 was associated with greater changes in CD40-CD40L pathway-related markers, including reductions in inflammatory and bone resorption markers (interleukin-6, matrix metalloproteinase-3, receptor activator of nuclear factor-kappaB ligand), concentration of autoantibodies (immunoglobulin [Ig]G rheumatoid factor [RF], IgM RF, IgA RF) and CD95+ activated B-cell subsets.	BI 655064	0-9	CD40 molecule	Homo sapiens	49-53	
30902820-8	2019	CONCLUSION: Although blockade of the CD40-CD40L pathway with BI 655064 in MTX-IR patients with RA resulted in marked changes in clinical and biological parameters, including reductions in activated B-cells, autoantibody production and inflammatory and bone resorption markers, with a favourable safety profile, clinical efficacy was not demonstrated in this small phase IIa study.	BI 655064	61-70	CD40 molecule	Homo sapiens	37-41